专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050058701A1 Active drug delivery in the gastrointestinal tract 审中-公开
标题翻译：活动药物在胃肠道输送
公开(公告)号：US20050058701A1
公开(公告)日：2005-03-17
申请号：US10901742
申请日：2004-07-29
申请人： Yossi Gross , Yoram Sela , Ziv Belsky , Rina Lev , Daniel Goldstein
发明人： Yossi Gross , Yoram Sela , Ziv Belsky , Rina Lev , Daniel Goldstein
IPC分类号： A61B1/05 , A61B5/00 , A61B5/03 , A61B5/07 , A61B17/32 , A61B18/02 , A61B18/14 , A61B18/20 , A61B19/00 , A61J3/07 , A61K9/00 , A61K9/22 , A61K9/48 , A61M31/00 , A61N1/05 , A61N1/30 , A61N1/32 , A61N1/36 , A61N1/372 , A61N1/375 , G01K13/00
CPC分类号： A61B1/041 , A61B1/00016 , A61B1/00156 , A61B5/0008 , A61B5/01 , A61B5/036 , A61B5/073 , A61B5/14532 , A61B5/14539 , A61B5/14546 , A61B5/4839 , A61B17/3203 , A61B18/02 , A61B18/14 , A61B18/20 , A61B34/70 , A61B34/72 , A61J3/07 , A61K9/0004 , A61K9/0009 , A61K9/0097 , A61K9/4808 , A61M31/002 , A61N1/05 , A61N1/306 , A61N1/325 , A61N1/327 , A61N1/36007 , A61N1/3605 , A61N1/37205 , A61N1/3756 , G01K13/002
摘要： Apparatus for drug administration is provided, including an ingestible capsule, which includes a drug, stored by the capsule, and an environmentally-sensitive mechanism, adapted to change a state thereof responsively to a disposition of the capsule within a gastrointestinal (GI) tract of a subject. The capsule further includes first and second electrodes, and a control component, adapted to facilitate passage of the drug, in response to a change of state of the environmentally-sensitive mechanism, through an epithelial layer of the GI tract by driving the first and second electrodes to apply a series of pulses at a current of less than about 5 mA, at a frequency of between about 12 Hz and about 24 Hz, and with a pulse duration of between about 0.5 milliseconds and about 3 milliseconds.
摘要翻译：提供了用于药物给药的装置，包括可摄入胶囊，其包括由胶囊储存的药物和环境敏感性机构，其适于改变其状态，其响应于胶囊在胃肠（GI）课程。胶囊还包括第一和第二电极以及控制部件，其适于响应于环境敏感性机构的状态改变而促进药物通过胃肠道的上皮层，通过驱动第一和第二电极以小于约5mA的电流施加一系列脉冲，频率为约12Hz至约24Hz，脉冲持续时间为约0.5毫秒至约3毫秒。

2. 发明授权

US08969417B2 Pharmaceutical compositions for treatment of Parkinsons disease 有权
标题翻译：用于治疗帕金森病的药物组合物
公开(公告)号：US08969417B2
公开(公告)日：2015-03-03
申请号：US12996455
申请日：2009-06-07
申请人： Itschak Lamensdorf , Yoram Sela
发明人： Itschak Lamensdorf , Yoram Sela
IPC分类号： A61K31/135 , A61K31/428 , A61K45/06 , A61K31/137 , A61K31/4045
CPC分类号： A61K31/428 , A61K31/135 , A61K31/137 , A61K31/277 , A61K31/4045 , A61K45/06 , A61K2300/00
摘要： Pharmaceutical compositions are provided for treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a fixed dose combination of two active agents selected from compounds having either neuroprotective or symptomatic effects, or both, in Parkinson's disease patients, wherein the molar ratio of the two compounds is in the range of 1:1 to 1:100. The compositions are formulated for immediate release, controlled release, or both immediate and controlled release.
摘要翻译：提供药物组合物用于治疗帕金森病，其包含药学上可接受的载体和在帕金森病患者中选择具有神经保护作用或症状作用的两种或两者的两种活性剂的固定剂量组合，其中两种化合物的摩尔比为在1：1至1：100的范围内。将组合物配制成立即释放，控制释放或立即释放和控制释放。

3. 发明授权

US08557282B2 Extended release compositions comprising as active compound venlafaxine hydrochloride 有权
标题翻译：包含作为活性化合物文拉法辛盐酸盐的延长释放组合物
公开(公告)号：US08557282B2
公开(公告)日：2013-10-15
申请号：US13301494
申请日：2011-11-21
申请人： Yoram Sela
发明人： Yoram Sela
IPC分类号： A61K9/26
CPC分类号： A61K9/5047 , A61K9/5026 , A61K9/5078
摘要： The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.
摘要翻译：本发明涉及包含作为活性化合物盐酸文拉法辛的延长释放组合物，其中盐酸文拉法辛涂覆在非帕拉尔惰性核心上，然后将涂覆的核心涂覆有能够控制盐酸文拉法辛的聚合物层。

4. 发明申请

US20120135082A1 EXTENDED RELEASE COMPOSITIONS COMPRISING AS ACTIVE COMPOUND VENLAFAXINE HYDROCHLORIDE 有权
标题翻译：包含活性化合物芬那福昔芬盐酸盐的扩展性释放组合物
公开(公告)号：US20120135082A1
公开(公告)日：2012-05-31
申请号：US13301494
申请日：2011-11-21
申请人： YORAM SELA
发明人： YORAM SELA
IPC分类号： A61K9/14 , A61P25/24 , A61K31/135 , B05D1/36 , A61K9/52
CPC分类号： A61K9/5047 , A61K9/5026 , A61K9/5078
摘要： The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.
摘要翻译：本发明涉及包含作为活性化合物盐酸文拉法辛的延长释放组合物，其中盐酸文拉法辛涂覆在非帕拉尔惰性核心上，然后将涂覆的核心涂覆有能够控制盐酸文拉法辛的聚合物层。

5. 发明申请

US20090069417A1 CAROTENOID OXIDATION PRODUCTS AS CHEMOPREVENTIVE AND CHEMOTHERAPEUTIC AGENTS 审中-公开
标题翻译： CAROTENOID氧化产品作为化学和化学药剂
公开(公告)号：US20090069417A1
公开(公告)日：2009-03-12
申请号：US12090174
申请日：2006-10-05
申请人： Yoav Sharoni , Joseph Levy , Yoram Sela , Zohar Nir
发明人： Yoav Sharoni , Joseph Levy , Yoram Sela , Zohar Nir
IPC分类号： A61K31/343 , A61K31/01 , A61K31/045 , A61K31/11 , A61P35/00 , A61K31/12 , A61K31/336
CPC分类号： A61K31/203 , A61K31/366
摘要： The present invention relates to a method for the chemoprevention and treatment of cancer, by administering a pharmaceutical composition comprising a carotenoid derivative, such as a derivative of lycopene, a- and b-carotene, phytoene, phytofluene, lutein, zeaxanthin, α- and β-cryptoxanthin, canthaxanthin, astaxanthin, or other carotenoid. The carotenoid derivative is a carotenoid oxidation product, and is preferably an aldehyde derivative, a dialdehyde derivative or a ketone derivative. The carotenoid derivative can be a derivative of any naturally occurring carotenoid, such as those found in tomatoes and other fruits and vegetables.
摘要翻译：本发明涉及一种化学预防和治疗癌症的方法，方法是通过施用包含类胡萝卜素衍生物的药物组合物，所述类胡萝卜素衍生物例如番茄红素，α-和β-胡萝卜素衍生物，八氢番茄红素，植物荧光素，叶黄素，玉米黄质，α-和 β-隐黄质，角黄素，虾青素或其他类胡萝卜素。类胡萝卜素衍生物是类胡萝卜素氧化产物，优选为醛衍生物，二醛衍生物或酮衍生物。类胡萝卜素衍生物可以是任何天然存在的类胡萝卜素的衍生物，例如在番茄和其他水果和蔬菜中发现的类胡萝卜素。

6. 发明申请

US20120301542A1 EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF 有权
标题翻译： RASAGILINE的延长释放配方及其用途
公开(公告)号：US20120301542A1
公开(公告)日：2012-11-29
申请号：US13577099
申请日：2011-02-03
申请人： Yoram Sela , Nurit Livnah , Itschak Lamensdorf , Tomer Madmon
发明人： Yoram Sela , Nurit Livnah , Itschak Lamensdorf , Tomer Madmon
IPC分类号： A61K31/136 , A61K9/52 , A61K9/22 , A61P25/28 , B29C43/02 , A61P25/00 , A61K31/13 , A61K31/137 , A61K31/138 , B05D7/00 , A61K9/50 , A61P25/16
CPC分类号： A61K9/5078 , A61K31/135
摘要： The present invention provides various pharmaceutical compositions, in particular for oral administration, formulated for extended release of active compounds useful in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and injuries to the nervous system. The active compound comprised within these compositions is preferably selected from N-propargyl-1-aminoindan, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, more preferably rasagiline or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供了用于口服给药的各种药物组合物，其用于延长释放用于治疗神经变性疾病，特别是帕金森病和活动性神经系统的活性化合物。包含在这些组合物中的活性化合物优选选自N-炔丙基-1-氨基茚满，其对映体或其药学上可接受的盐，更优选雷沙吉兰或其药学上可接受的盐。

7. 发明申请

US20100330178A2 EXTENDED RELEASE COMPOSITIONS COMPRISING AS ACTIVE COMPOUND VENLAFAXINE HYDROCHLORIDE 有权
标题翻译：包含活性化合物芬那福昔芬盐酸盐的扩展性释放组合物
公开(公告)号：US20100330178A2
公开(公告)日：2010-12-30
申请号：US10500634
申请日：2002-11-07
申请人： Yoram SELA
发明人： Yoram SELA
IPC分类号： A61K9/26 , A61K31/277
CPC分类号： A61K9/5047 , A61K9/5026 , A61K9/5078
摘要： The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.
摘要翻译：本发明涉及包含作为活性化合物盐酸文拉法辛的延长释放组合物，其中盐酸文拉法辛涂覆在非帕拉尔惰性核心上，然后将涂覆的核心涂覆有能够控制盐酸文拉法辛的聚合物层。

8. 发明申请

US20100291200A1 FORMULATIONS FOR POORLY SOLUBLE DRUGS 审中-公开
标题翻译：不良溶剂药物的配方
公开(公告)号：US20100291200A1
公开(公告)日：2010-11-18
申请号：US12843958
申请日：2010-07-27
申请人： Shlomo MAGDASSI , Yoram SELA , Keren COHEN
发明人： Shlomo MAGDASSI , Yoram SELA , Keren COHEN
IPC分类号： A61K9/66 , A61K9/28 , A61K9/14 , A61K9/50 , A61K9/107
CPC分类号： A61K9/1682 , A61K9/1635 , A61K9/1652 , A61K9/1658
摘要： The present invention provides a drug delivery system comprising nanoparticles or microparticles of a water poorly soluble drug dispersed in a polymeric bead containing essentially only of hydrophilic polymers (i.e. without hydrophobic polymers). The present invention further provides a method of producing the drug delivery system of the invention.
摘要翻译：本发明提供一种药物递送系统，其包含分散在基本上仅含有亲水性聚合物（即不含疏水性聚合物）的聚合物珠粒中的难溶于水的药物的纳米颗粒或微粒。本发明还提供了一种制备本发明的药物递送系统的方法。

9. 发明申请

US20090035369A1 Composition and Methods for Treating and Preventing Age-Related Macular Degeneration 审中-公开
标题翻译：治疗和预防年龄相关性黄斑变性的组合物和方法
公开(公告)号：US20090035369A1
公开(公告)日：2009-02-05
申请号：US12224376
申请日：2007-02-25
申请人： Yoram Sela
发明人： Yoram Sela
IPC分类号： A61K31/404 , A61K33/30 , A61K33/34 , A61K9/14 , A61K9/28 , A61K9/48 , A61K9/50 , A61P27/02
CPC分类号： A61K31/404
摘要： The present invention relates to methods and compositions effective in preventing, attenuating, inhibiting the progression of, and treating eye diseases, e.g., age-related macular degeneration (AMD). The compositions comprise, as an active ingredient, an effective amount of 3,3′-diindolylmethane (DIM) and/or its precursor indole-3-carbinol (I3C). The compositions can further comprise additional agents such as carotenoids and other phytochemicals, which produce a synergistic effect in preventing, attenuating, inhibiting the progression of, and treating AMD and other eye diseases such as glaucoma, cataracts and diabetic retinopathy (DR). The compositions are particularly effective in treating and preventing wet AMD, and in preventing or inhibiting the progression of dry AMD (non-neovascular) to wet AMD (neovascular).
摘要翻译：本发明涉及有效预防，减弱，抑制进展和治疗眼部疾病例如年龄相关性黄斑变性（AMD）的方法和组合物。组合物包含有效量的3,3'-二吲哚基甲烷（DIM）和/或其前体吲哚-3-甲醇（I3C）作为活性成分。组合物可进一步包含另外的试剂，例如类胡萝卜素和其它植物化学物质，其在预防，减弱，抑制AMD和其它眼睛疾病如青光眼，白内障和糖尿病性视网膜病变（DR）方面产生协同作用。该组合物在治疗和预防湿性AMD中以及在预防或抑制干性AMD（非新生血管）到湿性AMD（新生血管））的进展中特别有效。

10. 发明申请

US20180116961A1 STIMULANT ABUSE-DETERRENT COMPOSITIONS 审中-公开
公开(公告)号：US20180116961A1
公开(公告)日：2018-05-03
申请号：US15572951
申请日：2016-05-11
申请人： Yoram Sela , Itschak Lamensdorf
发明人： Yoram Sela , Itschak Lamensdorf
IPC分类号： A61K9/16 , A61K9/28 , A61K9/48 , A61K9/00 , A61K31/137 , A61K31/4458 , A61K31/473 , A61K31/485 , A61K45/06 , C07D221/18 , C07D211/34 , A61P25/00
CPC分类号： A61K9/1676 , A61K9/0002 , A61K9/0053 , A61K9/1623 , A61K9/2886 , A61K9/4808 , A61K9/4858 , A61K9/5078 , A61K9/5084 , A61K31/137 , A61K31/165 , A61K31/445 , A61K31/4458 , A61K31/4468 , A61K31/4535 , A61K31/454 , A61K31/473 , A61K31/485 , A61K36/74 , A61K45/06 , A61K2300/00 , A61P25/00 , C07D211/34 , C07D221/18 , C07D401/06 , C07D409/06 , C07D489/02
摘要： The present invention provides an abuse deterrent oral fixed-dose composition, comprising a stimulant or opioid and an abuse deterrent active, wherein the abuse deterrent active is configured to be bioavailable only when the composition is crushed, ground or dissolved.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式